Cannabis May Be Useful In Treating Alzheimer’s

Researchers from Tel-Aviv University’s Abarbanel Mental Health Center have found the use of medicinal cannabis could improve the lives of Alzheimer’s patients.

As the world’s population is generally living longer, dementia conditions such as Alzheimer’s disease are increasing in prevalence. According to FightDementia, just in Australia alone there are 342,800 people living with dementia and that number is expected to grow to almost 900,000 by 2050.

Alzheimer’s is a devastating condition, so the race is on not only to find a vaccine and a cure, but also ways of better managing it.

The TAU study involved eleven Alzheimer patients who participated an open label, 4 week long prospective trial to determine the effects of tetrahydrocannabinol (THC), the psychoactive compound in cannabis. Ten patients completed the trial – and with some very promising results.

Not all of the limited research to date has been positive. Another small study found pills containing THC were no better than placebos in alleviating symptoms such as agitation, aggression and wandering. However, the dosage was low and well tolerated, so the researchers are considering a new trial using higher dosages.

On a related note – another interesting medical cannabis related discovery recently made at Tel-Aviv University occurred last year, when researchers determined the administration of cannabidiol (CBD) significantly helps heal bone fractures. CBD is a non-psychotropic cannabinoid that is believed to have a therapeutic effect in treating other conditions, such as epilepsy.

Lead researcher Dr. Yankel Gabet said the effect on bone healing was so marked, it was “simply undeniable“.

Gillian Jalimnson is one of Hemp Gazette's staff writers and has been with us since we kicked off in 2015. Gillian sees massive potential for cannabis in areas of health, energy, building and personal care products and is intrigued by the potential for cannabidiol (CBD) as an alternative to conventional treatments. You can contact Gillian here.